Presentation on Spinal Metastases Scorng system and Decision making
By
Dr.SHASHIDHAR B K
Bangalore Spine Specialist Clinic
www.spinesurgeonbangalore.com
drshashidharbk@gmail.com
A comprehensive presentation on the epidemiology, pathophysiology, clinical presentation, decision making and treatment options of spinal metastases. Supported with the best available evidence as of October 6, 2008
Presentation on Spinal Metastases Scorng system and Decision making
By
Dr.SHASHIDHAR B K
Bangalore Spine Specialist Clinic
www.spinesurgeonbangalore.com
drshashidharbk@gmail.com
A comprehensive presentation on the epidemiology, pathophysiology, clinical presentation, decision making and treatment options of spinal metastases. Supported with the best available evidence as of October 6, 2008
Title: Understanding Giant Cell Tumor of Bone: A Comprehensive Overview
Introduction:
Giant Cell Tumor of Bone (GCTB) is a rare but potentially aggressive bone tumor that primarily affects young adults. While typically benign, it can be locally destructive and lead to significant morbidity if not managed appropriately. This presentation aims to provide a comprehensive understanding of GCTB, including its epidemiology, pathogenesis, clinical presentation, diagnostic modalities, treatment options, and prognosis.
Epidemiology:
GCTB accounts for approximately 5% of all primary bone tumors, with a peak incidence in the third and fourth decades of life. It shows a slight female predilection and commonly arises in the epiphyseal regions of long bones, particularly around the knee.
Pathogenesis:
The exact etiology of GCTB remains elusive, but it is thought to arise from mesenchymal stromal cells. Genetic alterations, including mutations in the H3F3A gene, have been implicated in its pathogenesis. Additionally, dysregulation of the RANK/RANKL/OPG pathway plays a crucial role in the development and progression of GCTB.
Clinical Presentation:
Patients with GCTB typically present with localized bone pain, swelling, and limited range of motion at the affected joint. Pathologic fractures may occur, especially in larger lesions. Rarely, patients may present with systemic symptoms such as fever and weight loss.
Diagnostic Modalities:
Diagnostic evaluation of GCTB includes imaging studies such as plain radiographs, which often show characteristic lytic lesions with well-defined margins and cortical thinning. Magnetic resonance imaging (MRI) provides detailed soft tissue evaluation and aids in surgical planning. Biopsy remains the gold standard for definitive diagnosis.
Treatment Options:
The management of GCTB is challenging and requires a multidisciplinary approach. Treatment options include curettage with or without adjuvant therapy (such as adjuvant bone cement, phenol, or cryotherapy), en bloc resection for aggressive or recurrent tumors, and denosumab therapy for unresectable or metastatic disease. Close surveillance is essential due to the risk of local recurrence.
Prognosis:
The prognosis of GCTB is generally favorable, with a low incidence of metastasis. However, local recurrence rates range from 10% to 50%, depending on the extent of surgical resection and the use of adjuvant therapy. Long-term follow-up is necessary to monitor for recurrence and late complications.
Conclusion:
In conclusion, Giant Cell Tumor of Bone poses a significant clinical challenge due to its potential for local recurrence and morbidity. Early diagnosis, appropriate staging, and a tailored treatment approach are crucial for optimizing patient outcomes. Continued research into the molecular mechanisms underlying GCTB pathogenesis and the development of targeted therapies are essential for improving treatment strategies and patient prognosis. Giant Cell Tumor of Bone (GCTB)
EMGuideWire's Radiology Reading Room: Lung CancerSean M. Fox
The Department of Emergency Medicine at Carolinas Medical Center is passionate about education! Dr. Michael Gibbs is a world-renowned clinician and educator and has helped guide numerous young clinicians on the long path of Mastery of Emergency Medical Care. With his oversight, the EMGuideWire team aim to help augment our understanding of emergent imaging. You can follow along with the EMGuideWire.com team as they post these monthly educational, self-guided radiology slides or you can also use this section to learn more in-depth about specific conditions and diseases. This Radiology Reading Room pertains to Lung Cancer and is brought to you by Oriane Longerstaey, MD and Danielle Aument, PA. Special Guest Editors are Jeffrey Hagen, MD and Jaspal Singh, MD.
Title: Understanding Giant Cell Tumor of Bone: A Comprehensive Overview
Introduction:
Giant Cell Tumor of Bone (GCTB) is a rare but potentially aggressive bone tumor that primarily affects young adults. While typically benign, it can be locally destructive and lead to significant morbidity if not managed appropriately. This presentation aims to provide a comprehensive understanding of GCTB, including its epidemiology, pathogenesis, clinical presentation, diagnostic modalities, treatment options, and prognosis.
Epidemiology:
GCTB accounts for approximately 5% of all primary bone tumors, with a peak incidence in the third and fourth decades of life. It shows a slight female predilection and commonly arises in the epiphyseal regions of long bones, particularly around the knee.
Pathogenesis:
The exact etiology of GCTB remains elusive, but it is thought to arise from mesenchymal stromal cells. Genetic alterations, including mutations in the H3F3A gene, have been implicated in its pathogenesis. Additionally, dysregulation of the RANK/RANKL/OPG pathway plays a crucial role in the development and progression of GCTB.
Clinical Presentation:
Patients with GCTB typically present with localized bone pain, swelling, and limited range of motion at the affected joint. Pathologic fractures may occur, especially in larger lesions. Rarely, patients may present with systemic symptoms such as fever and weight loss.
Diagnostic Modalities:
Diagnostic evaluation of GCTB includes imaging studies such as plain radiographs, which often show characteristic lytic lesions with well-defined margins and cortical thinning. Magnetic resonance imaging (MRI) provides detailed soft tissue evaluation and aids in surgical planning. Biopsy remains the gold standard for definitive diagnosis.
Treatment Options:
The management of GCTB is challenging and requires a multidisciplinary approach. Treatment options include curettage with or without adjuvant therapy (such as adjuvant bone cement, phenol, or cryotherapy), en bloc resection for aggressive or recurrent tumors, and denosumab therapy for unresectable or metastatic disease. Close surveillance is essential due to the risk of local recurrence.
Prognosis:
The prognosis of GCTB is generally favorable, with a low incidence of metastasis. However, local recurrence rates range from 10% to 50%, depending on the extent of surgical resection and the use of adjuvant therapy. Long-term follow-up is necessary to monitor for recurrence and late complications.
Conclusion:
In conclusion, Giant Cell Tumor of Bone poses a significant clinical challenge due to its potential for local recurrence and morbidity. Early diagnosis, appropriate staging, and a tailored treatment approach are crucial for optimizing patient outcomes. Continued research into the molecular mechanisms underlying GCTB pathogenesis and the development of targeted therapies are essential for improving treatment strategies and patient prognosis. Giant Cell Tumor of Bone (GCTB)
EMGuideWire's Radiology Reading Room: Lung CancerSean M. Fox
The Department of Emergency Medicine at Carolinas Medical Center is passionate about education! Dr. Michael Gibbs is a world-renowned clinician and educator and has helped guide numerous young clinicians on the long path of Mastery of Emergency Medical Care. With his oversight, the EMGuideWire team aim to help augment our understanding of emergent imaging. You can follow along with the EMGuideWire.com team as they post these monthly educational, self-guided radiology slides or you can also use this section to learn more in-depth about specific conditions and diseases. This Radiology Reading Room pertains to Lung Cancer and is brought to you by Oriane Longerstaey, MD and Danielle Aument, PA. Special Guest Editors are Jeffrey Hagen, MD and Jaspal Singh, MD.
This presentation consist MR procedure of pelvis and hip joint , anatomy and MR planning is shown by picture with positioning block and parameters are included ,it includes basic sequence of both procedures
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...rowala30
Alka magic plan 1350 -we deliver alkaline water at your door step and you can make handsome money by referral programme
we also help and provide systematic guideline to setup 1000 lph alkaline water plant
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Veterinary Diagnostics Market PPT 2024: Size, Growth, Demand and Forecast til...IMARC Group
The global veterinary diagnostics market size reached US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.3% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-diagnostics-market
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
This document is designed as an introductory to medical students,nursing students,midwives or other healthcare trainees to improve their understanding about how health system in Sri Lanka cares children health.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
3. Molecular mechanisms of metastasis
• Analysis of 735 autopsy records of breast
cancer patients
• Identified a non-random pattern of
metastases
• The Lancet 1889 : ‘seed and soil hypothesis’
Dr Stephen Paget
Surgeon & pathologist
1855-1926
4. Metastatic cells
• Small aggressive population
• Not all circulating cancer cells form a
metastasis
• Animal models show that 100s of cells detach
and circulate each day
• 0.1% are viable 24 hours later
• 0.01% form a metastasis
5. Origin & distribution
• Types of tumour spread to bone
o Breast
o Prostate
o Lung
o Kidney
o Thyroid
• Differential: myeloma and lymphoma
• Skeleton is ⅓ most favoured site for metastasis
of solid tumours (after liver and lung)
6. Frequency of skeletal metastases at
autopsy
Tumour Bone metastases (%)
Breast
Prostate
Thyroid
Kidney
Lung
Oesophagus
GI tract/colon
Rectum
Bladder
Uterine/cervix
Ovaries
Liver
Melanoma
50-85
60-85
28-60
33-60
32-64
6
3-10
8-60
42
50
9
16
7
7. Clinical features of bony metastases
• Bone pain
• Pathological fracture
• Nerve compression
• Hypercalcaemia
8. Bone pain
• Frequent in all lesion types
• Exact mechanisms unclear
• Remissions and exacerbations
– No obvious change in lesions
10. Nerve compression
• Vertebral # and deformity
• Direct pressure on spinal cord by metastasis
• Osteoblastic lesion overgrowth
• Skull lesion- impingement on foramina
11. Hypercalcaemia
• Common: particularly osteolytic metastases
• Less common in prostate cancer
• 30% breast cancer patients at some point during
illness course (usually late on)
• Causes:
– Excessive bone resorption
– Impairment renal calcium excretion
• CHECK PTH before treatment if originating cause
unknown
• Treat with i.v. bisphosphonate
12. Surgical management
• Approx 1.5% of patients with bone metastases
require surgery (pre or post #)
• Stabilise long bones prior to #
• Spine
– Cord compression
– Instability
– Occasionally amenable to
vertebroplasty/kyphoplasty
• Radiofrequency ablation increasing in use
Urgent
decompression &
stabilisation
13. Relative Contraindications
• Moribund patient
• Infected wound in surgical region
• Acute DVT, especially if accompanying PE
• Extensive neurovascular encasement by soft
tissue tumour extension
• Severe malnutrition
• Short expected survival
14. Planning surgery
• CT useful for pre-op planning
• Goal is early return to reasonable function/weight bearing
• Reconstruction nail for femur (pertrochanteric and shaft)
• No indication for standard femoral nail
• Bipolar for neck/head metastases (ensure no significant acetabular
metastases)
• Retrograde nail only if adjacent previous THR
• Various i.m. nails for humerus
• Cement (with antibiotics and anticancer agents) to fill large defects
• Massive endoprostheses or arthroplasty
– Large diffuse areas of destruction (usually already fractured)
– Lesions affecting adjacent joints
• Minimal role for plates and screws
15. Final points
• Does IM nailing embolise metastases?
– No evidence in animal models
– No clear evidence that unreamed nailing is safer
• There is a significant risk of intra and
postoperative PE
– Surgical & anaesthetic team must be on the alert
– Pulse lavage in between reaming may reduce the
risk
– Venting reduces pressure (cadaver study)
17. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=8
6 month # risk 15%
72 year old lady with known breast cancer
18. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score 10
6 month # risk 72%
19. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=8
6 month # risk 15%
20.
21. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=10
6 month # risk 72%
54 year old with known breast ca
22.
23.
24. 77 year old with breast cancer : 6 years bony mets (refused all treatment)
Score=10
6 month # risk 72%
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
27. 64 year old breast ca 8 years previously: mastectomy & good response to treatment
Referred to orthopaedic clinic with thoracic back pain: bone scan requested
Developed neurological symptoms 2 weeks later
28.
29. 66 year old male with
Multiple Myeloma
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=8
6 month # risk 15%
30. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=10
6 month # risk 72%
2 months later
34. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=11
6 month # risk 96%
Already fractured
35.
36.
37.
38. 71 year old female, breast ca 1977
& 2003, 2 years elbow pain & stiffness
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=7
6 month # risk 4%
40. Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=9
6 month # risk 33%
41.
42.
43. 81 year old gentleman
with known prostate ca
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=7
6 month # risk 4%
44. Spinal involvement in 80% of advanced prostate carcinoma patients &
6% develop cord compression
45. 58 year old gentleman- fatigue & lower leg pain & swelling several months
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=10
6 month # risk 72%
46.
47. Feeding vessel
REFERRED FOR EMBOLISATION
Renal carcinoma cells express large amounts
of HIF and VEGF-results highly vascular bony metastases
48. 61 year old gentleman- fatigue & lower leg pain & swelling several months
Score 1 2 3
Pain Mild Moderate Functional
Site Upper limb Lower limb Per troch
Size ⅓ ⅓-⅔ >⅔
Type Blastic Mixed Lytic
Score=10
6 month # risk 72%